Literature DB >> 6930318

Improved treatment results in the management of single and multiple relapses of acute lymphoblastic leukemia.

G H Reaman, S Ladisch, C Echelberger, D G Poplack.   

Abstract

One hundred twenty-five hematologic relapses of acute lymphoblastic leukemia (ALL) were treated with a four-drug reinduction regimen consisting of L-asparaginase, vincristine, daunomycin, and prednisone (Asp-VDP). Complete remission was achieved in 114 of 125 (91%) treatment courses. The regimen also proved to be highly effective in the management of multiple subsequent relapses which occurred in patients who had previously attained complete remissions with this regimen. The rates of remission induction for second and third reinduction attempts were 89% and 90%, respectively. Ten patients received this regimen for the treatment of four or more consecutive relapses and achieved complete remissions on each occasion. Toxicities related to therapy were not excessive. Although myelosuppression was the most frequently encountered toxicity, documented infection complicated only 14% of the treatment courses. These results constitute a considerable improvement in the management of recurrent ALL.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6930318     DOI: 10.1002/1097-0142(19800615)45:12<3090::aid-cncr2820451235>3.0.co;2-f

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

1.  Polyethylene Glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a Children's Oncology Group Study (POG 8866).

Authors:  Joanne Kurtzberg; Barbara Asselin; Mark Bernstein; George R Buchanan; Brad H Pollock; Bruce M Camitta
Journal:  J Pediatr Hematol Oncol       Date:  2011-12       Impact factor: 1.289

2.  Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase.

Authors:  Shotaro Iwamoto; Keichiro Mihara; James R Downing; Ching-Hon Pui; Dario Campana
Journal:  J Clin Invest       Date:  2007-03-22       Impact factor: 14.808

3.  Use of a synthetic protease inhibitor for the treatment of L-asparaginase-induced acute pancreatitis complicated by disseminated intravascular coagulation.

Authors:  M Murakawa; T Okamura; T Shibuya; M Harada; T Otsuka; Y Niho
Journal:  Ann Hematol       Date:  1992-05       Impact factor: 3.673

4.  Improvement of induction remission rate by modifying the dose of idarubicin for relapsed childhood acute lymphoblastic leukemia.

Authors:  Jong Hyung Yoon; Jeong Ah Park; Eun Kyung Kim; Hyoung Jin Kang; Hee Young Shin; Hyo Seop Ahn
Journal:  J Korean Med Sci       Date:  2009-04-20       Impact factor: 2.153

5.  Vindesine, prednisone, and daunomycin in acute lymphoblastic leukemia in relapse.

Authors:  G Garay; J Milone; E Dibar; S Pavlovsky; R Kvicala; F Sackmann Muriel; D Montres Varela; M Eppinger-Helft
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

6.  Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected].

Authors:  Elizabeth A Raetz; Michael J Borowitz; Meenakshi Devidas; Stephen B Linda; Stephen P Hunger; Naomi J Winick; Bruce M Camitta; Paul S Gaynon; William L Carroll
Journal:  J Clin Oncol       Date:  2008-08-20       Impact factor: 44.544

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.